| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
11-21-2008, 10:08 AM
|
#1 | |||
|
||||
|
Magnate
|
Oxford BioMedica Announces Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial in Parkinson’s Disease
OXFORD, England, Nov. 19, 2008 - Improvements in Motor Function Maintained at Six Months - http://www.pharmalive.com/News/index...&categoryid=40
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller |
|||
|
 Reply With Quote
|
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| ProSavin trial | Parkinson's Disease Clinical Trials | |||
| Prosavin (gene therapy) trial kicks off ... | Parkinson's Disease | |||
| Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-76 | ALS News & Research | |||
| Safinamide..Merck Serono Announces 18-Month Safety and Efficacy Data Phase III Trial | Parkinson's Disease Clinical Trials | |||
Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial
Threaded Mode